Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as adults, women only.

Infertile women who satisfied the Bologna criteria for poor responders were randomized into GH treatment and control groups.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This was a single-center, randomized, open-label, parallel study.

The baseline characteristics and IVF outcomes were compared between the two groups.

What Was Measured

The subject headings attached to it are Anti-Mullerian Hormone, Chorionic Gonadotropin, Embryo Implantation, Embryo Transfer, Fertilization in Vitro, Growth Hormone and Infertility, Female.

Author keywords: Oocytes.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Archives of gynecology and obstetrics), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.